ARS Pharmaceuticals recently received FDA approval for neffy, epinephrine in a nasal spray format for the treatment of allergic reactions like anaphylaxis

blonca9
Sep 30, 2024
1 min read

CEO Richard Lowenthal explains the science behind how it works, describes the launch plans, and discusses an additional indication to be tested in the pipeline.

Recent Posts

See All

Talking chromatin regulation at Foghorn Therapeutics - whose partner Lilly will have preclinical data at AACR highlighting how the lead SMARCA2 program could do in combinations with other therapies

AI news: Epicrispr Biotechnologies' CEO Amber Salzman describes how her company will be utilizing AI muscle analysis in its clinical study for facioscapulohumeral muscular dystrophy

Lexeo Therapeutics' CEO Nolan Townsend highlights recent FA cardiomyopathy data and the path ahead in that indication. Plus, the latest on PKP2 ACM, and more

ARS Pharmaceuticals recently received FDA approval for neffy, epinephrine in a nasal spray format for the treatment of allergic reactions like anaphylaxis

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight